Global Kidney Cancer Therapeutics and Diagnostics Market to Reach USD 9.2 Billion by 2033, Stimulated by Rising Prevalence of Kidney Cancer

December 17, 2024 | Healthcare

According to the latest report by IMARC Group, titled “Kidney Cancer Therapeutics and Diagnostics Market Report by Component (Drugs, Diagnostics), Cancer Types (Clear Cell RCC, Papillary RCC, Chromophobe RCC, Transitional Cell Carcinoma, and Others), Application (Hospitals, Pharmaceutical Labs, Genomic Laboratories, and Others), and Region 2025-2033,” the global kidney cancer therapeutics and diagnostics market size reached USD 5.4 Billion in 2024. Kidney cancer, also known as renal cancer, is diagnosed through a combination of medical history assessment, physical examination, and tests like computed tomography (CT) scan, ultrasound, magnetic resonance imaging (MRI), and positron emission tomography (PET). It can also be diagnosed through biopsy and blood and urine tests. Besides this, its therapeutics encompass a range of treatment options aimed at managing and combating the growth of cancerous cells. It includes various therapies and surgeries, such as radical or partial nephrectomy, which help remove the tumor and affected kidney tissue. Additionally, kidney cancer therapeutics and diagnostics are used for removing cancer cells, controlling the spread, destroying tumors, and assisting physicians in planning treatments.

Global Kidney Cancer Therapeutics and Diagnostics Market Trends:

The increasing prevalence of kidney cancer worldwide due to the aging population, lifestyle factors like smoking and obesity, and genetic predisposition represent one of the key factors driving the market. Additionally, the rising awareness among individuals about kidney cancer symptoms and the importance of early detection and treatment are catalyzing the demand for kidney cancer therapeutics and diagnostics. Apart from this, the increasing use of genomic and personalized medicine for effective treatment approaches is contributing to the market growth. Furthermore, governing agencies of several countries are introducing awareness campaigns and healthcare programs, which is offering a favorable market outlook. Moreover, advancements in targeted therapies, immunotherapies, and personalized medicine and the development of more advanced diagnostic technologies, like novel imaging methods, liquid biopsies, genomic testing, and artificial intelligence (AI)-driven diagnostic tools, are propelling the market growth. Besides this, a rise in the improvement of healthcare infrastructure and facilities are positively influencing the market. Looking forward, the market value is projected to reach USD 9.2 Billion by 2033, expanding at a CAGR of 5.9% during 2025-2033.

Market Summary:

  • Based on the component, the market has been bifurcated into drugs [drugs by therapeutic class {targeted therapy, immunotherapy, and others} and drugs by pharmacological class {angiogenesis inhibitors, mTOR inhibitors, monoclonal antibodies, and cytokine immunotherapy (II-2)}] and diagnostics [imaging test, biopsy, blood test, and others]. Drugs currently dominate the market, holding the largest share.
  • On the basis of the cancer types, the market has been divided into clear cell RCC, papillary RCC, chromophobe RCC, transitional cell carcinoma, and others. Clear cell RCC represents the largest market segment.
  • Based on the application, the market has been divided into hospitals, pharmaceutical labs, genomic laboratories, and others. At present, hospitals exhibit a clear dominance in the market.
  • Region-wise, the market has been categorized into North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. Amongst these, North America enjoys the leading position in the market.
  • The competitive landscape of the market has also been examined, with some of the key players being Bristol-Myers Squibb Company, Exelixis Inc., Genentech Inc. (Roche Holding AG), Novartis AG, and Pfizer Inc.


Report Scope:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Components Covered
  • Drugs: Drugs by Therapeutic Class, Drugs by Pharmacologic Class
  • Diagnostics: Imaging Test, Biopsy, Blood Test, Others
Cancer Types Covered Clear Cell RCC, Papillary RCC, Chromophobe RCC, Transitional Cell Carcinoma, Others
Applications Covered Hospitals, Pharmaceutical Labs, Genomic Laboratories, and Others
Regions Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Bristol-Myers Squibb Company, Exelixis Inc., Genentech Inc. (Roche Holding AG), Novartis AG, Pfizer Inc., etc.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.


Contact Us:

IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Kidney Cancer Therapeutics and Diagnostics Market to Reach USD 9.2 Billion by 2033, Stimulated by Rising Prevalence of Kidney Cancer
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials